Back
ESC2025 Premium Access

Pharmacogenetics for mavacamten treatment individualization in patients with obstructive hypertrophic cardiomyopathy

Session: Hypertrophic cardiomyopathy (1)
Topic: Hypertrophic Cardiomyopathy
Speaker: Miss C. Lucas (Marseille, FR)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Miss Claire Lucas

Aix-Marseille University, Marseille (France)
0 follower

3 more presentations in this session

Incidence and prevalence of hypertrophic cardiomyopathy in Sweden during the years 2003-2022, a nationwide observational study

Speaker: Doctor J. Silverdal (Gothenburg, SE)

Access
Abstract
Slides
Video
Like
Thumbnail

Implication of angio-based microvascular resistance for atrial fibrillation in patients with hypertrophic cardiomyopathy

Speaker: Doctor Y. Pei (Beijing, CN)

Access
Abstract
Slides
Video
Like
Thumbnail

Hypercontractile phenotype in hypertrophic cardiomyopathy correlate with adverse systemic and coronary parameters

Speaker: Professor K. Wierzbowska-Drabik (Lodz, PL)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Hypertrophic cardiomyopathy (1)

Speakers: Miss C. Lucas, Doctor J. Silverdal, Doctor Y. Pei, Professor K. Wierzbowska-Drabik
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources